

11 May 2018

Our Ref: RFI 23188

Dear Ms Thomason

**Freedom of Information Act 2000
Information in Relation to Non-Small Cell Lung Cancer**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 10 April 2018.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

**Catherine Treanor (Miss)
Information Governance Assistant**

Please provide the following information relating to NSCLC¹ patients treated² by your Trust in the 3 months, December 2017 to February 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and / or stage, please indicate accordingly within the tables below.

The information requested is not held centrally in relation to patients who were treated for Non-Small Cell Lung Cancer (NSCLC) in the last 3 months.

To obtain same would require a manual review of more than one electronic system as patients being treated for cancer incorporates the following areas, Surgery, chemotherapy, follow-up and endoscopy.

Given the number of records concerned, this would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this letter acts as a Refusal Notice.

However, the Trust can advise that there were 40 new patients diagnosed with C33 and C44 between December 2017 and February 2018. Of these 6 had a small cell diagnosis and 8 had a clinical lung cancer with no pathology.

| | Total number treated Stage IIIB/IV NSCLC Patients | If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided: | |
|---|--|--|--|
| Patients with NSCLC Stage IIIB/IV (Stage 3b/4) ³ | There were 40 new patients diagnosed with C33 and C44 between December 2017 and February 2018. Of these 6 had a small cell diagnosis and 8 had a clinical lung cancer with no pathology. | Total number NSCLC patients | |
| | | Other (please specify) | |
| | | Data not held/accessible | |

¹ ICD10 C33, C34

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

³ TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1
Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.

| | Total number treated Stage IIIB/IV NSCLC Patients | If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided: | |
|--|--|--|--|
| Docetaxel (mono or combination therapy) | None | Total number NSCLC patients | |
| | | Other (please specify) | |
| | | Data not held/accessible | |
| Atezolizumab (Tecentriq) | None | Total number NSCLC patients | |
| | | Other (please specify) | |
| | | Data not held/accessible | |
| Nivolumab (Opdivo) | None | Total number NSCLC patients | |
| | | Other (please specify) | |
| | | Data not held/accessible | |
| Pembrolizumab (Keytruda) | None | Total number NSCLC patients | |
| | | Other (please specify) | |
| | | Data not held/accessible | |

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:
